| 効果 | なし |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 30 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満, 肥満 |
この研究の注釈：
A dose-scaling open label study using four doses of pycnogenol (50mg, 100mg, 200mg, and 300mg) each for three sequential weeks noted a dose-dependent or time-dependent effect peaking after nine weeks (the 200mg dose) and maintaining for the remaining three weeks with 300mg pycnogenol. The parameter measured was blood glucose in type II diabetics, and the magnitude of reduction was 11-13%.
A dose-scaling open label study using four doses of pycnogenol (50mg, 100mg, 200mg, and 300mg) each for three sequential weeks noted a dose-dependent or time-dependent effect peaking after nine weeks (the 200mg dose) and maintaining for the remaining three weeks with 300mg pycnogenol. The parameter measured was blood glucose in type II diabetics, and the magnitude of reduction was 11-13%.
HbA1c also decreased from 8.02% down to 7.37%, this reached significance after nine weeks and endothelin-1 was similarly decreased (104+/-16pg/mL down to 91+/-15pg/mL) although reaching significance after six weeks; 300mg did not outperform 200mg on any parameter.
Insulin and its secretion appeared to be unaffected.
研究の資金源に関する問題点：
Funded by Horphag Research, a producer of pycnogenol
